Codis Accelerates Growth with 1315 Capital Investment

Codis Secures Funding for Expansion

Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK.

Enhancing Manufacturing Capabilities

The latest investment from 1315 Capital, along with support from existing investors BroadOak Capital Partners and Research Corporation Technologies (RCT), will accelerate the expansion of Codis's manufacturing capacity. With a commitment to improving support for its clients, this move is expected to lead to enhanced production and service offerings for pharmaceuticals and nutraceuticals.

Current Manufacturing Footprint

Codis operates an impressive total of over 400,000 square feet of current Good Manufacturing Practice (cGMP) facilities across multiple locations, including St. Louis and Seymour. It boasts a diverse technology suite, including large-scale spray drying operations that are crucial for modern drug formulation techniques.

Growing Market Demand

Pioneering the field of amorphous solid dispersions and particle engineering, Codis addresses the increasing necessity for specialized spray-drying methods within the pharmaceutical industry. These techniques are essential for producing drug substances that require intricate formulations and enhanced solubility.

Leadership Remarks on the Investment

Nicolas Fortin, the CEO of Codis, expressed enthusiasm regarding the partnership with 1315 Capital, stating, "We're thrilled to welcome 1315 Capital alongside RCT and BroadOak; this investment enables us to expand capacity in Haverhill to better support customers scaling to commercial supply." This sentiment highlights Codis's commitment to enhancing its production capabilities.

Matthew Reber, a partner at 1315 Capital, emphasized the importance of such investments, noting, "The pharmaceutical industry increasingly needs spray-drying expertise to produce advanced formulations, and we are proud to partner with Codis in this expansion."

Expanding Global Reach

The strategic funding not only builds on Codis’s existing production strengths but also emphasizes the company's global reach, ultimately leading to shorter supply timelines for customers. This investment is seen as a pivotal step toward solidifying Codis’s position as a leader in commercial spray drying.

About Codis

Codis stands out as a premier global CDMO, offering a wide range of manufacturing services focused on spray drying, amorphous solid dispersions, and particle engineering. The company caters to the needs of the pharmaceutical, consumer health, and nutraceutical industries, leveraging decades of combined expertise to deliver high-quality products and services.

Frequently Asked Questions

What is the purpose of Codis's new funding?

The funding aims to expand Codis's commercial manufacturing capacity at its Haverhill facility in the UK to better support its customers.

Who are the investors involved in this growth capital?

The primary investor is 1315 Capital, with support from BroadOak Capital Partners and Research Corporation Technologies (RCT).

What services does Codis specialize in?

Codis specializes in spray drying, amorphous solid dispersions, particle engineering, and finished-dose manufacturing in the pharmaceutical and nutraceutical sectors.

Why is spray drying important for pharmaceuticals?

Spray drying is a crucial technology that enhances the solubility and bioavailability of drug substances, making it essential in modern pharmaceutical manufacturing.

What is Codis's manufacturing footprint?

Codis operates over 400,000 square feet of cGMP facilities across St. Louis, Seymour, and Haverhill, which enables efficient large-scale spray drying.

About The Author

Riley Hayes here, a financial writer and specialist committed to assisting individuals in navigating the intricate world of finance. My love is using my blog and articles to simplify complex financial ideas into understandable, doable guidance. Having worked in finance for many years, I try to give my readers the information and resources they need to make wise financial choices.

Writing for several financial blogs has let me connect with a wide range of readers, from novice investors seeking new ideas to seasoned investors. My mission is to make money interesting and approachable so you may take charge of your financial future. I appreciate you traveling with me toward success and financial literacy.

Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.